Diabetic Retinopathy: What to Know

Diabetic retinopathy is the leading cause of new blindness in working-age adults in developed countries — a distinction that reflects both how common it is (affecting approximately 40% of adults with Type 2 diabetes and nearly all adults with Type 1 diabetes of 20 years duration) and how preventable the vision loss it causes truly is with proper screening, blood glucose control, and timely treatment. The challenge with diabetic retinopathy is that it is completely asymptomatic in its early and intermediate stages — the blood vessel damage that is progressing in the retina causes no pain, no blurring, no floaters, and no other symptoms until it has reached a stage where vision is already affected. This means that many adults with significant retinal damage first learn about it at an eye exam performed for a different reason, or worse, experience a sudden vision-threatening complication (vitreous hemorrhage, retinal detachment) without any warning. Understanding the stages of diabetic retinopathy, what each stage means for vision risk, what treatment options exist, and how annual eye exams detect and interrupt progression before vision loss occurs is essential knowledge for every adult with diabetes.

The Stages of Diabetic Retinopathy: From Early to Vision-Threatening

Diabetic retinopathy progresses through defined stages that reflect increasing severity of retinal blood vessel damage. Understanding the stages helps adults with diabetes understand their current eye health status and the urgency of monitoring and treatment at each stage:

• Mild non-proliferative diabetic retinopathy (NPDR): The earliest detectable stage of diabetic retinopathy, characterized by microaneurysms — tiny balloon-like swellings in the walls of the retinal capillaries where the vessel wall has been weakened by hyperglycemia. Microaneurysms appear as small red dots on retinal photography or fundus examination. At this stage, vision is typically not affected and the retinopathy may be reversible with aggressive blood glucose control. Annual monitoring continues, and the goal is preventing progression rather than treating the retina directly.
• Moderate non-proliferative diabetic retinopathy: As retinal capillary damage progresses, additional findings appear: retinal hemorrhages (blood leaking from damaged capillary walls — appearing as small red blots or flame-shaped hemorrhages depending on depth in the retina), hard exudates (yellowish-white deposits of lipids and proteins leaking from damaged vessels), and cotton wool spots (white areas representing localized retinal ischemia from capillary occlusion). Vision may still be unaffected unless macular edema (fluid accumulation at the center of the retina) develops. Monitoring frequency typically increases to every 6–12 months at this stage.
• Severe non-proliferative diabetic retinopathy (pre-proliferative): Extensive retinal ischemia from capillary closure — causing large areas of the retina to be deprived of oxygen — releases angiogenic signals (particularly vascular endothelial growth factor, VEGF) that drive the growth of new abnormal blood vessels. The 4-2-1 rule describes the severe NPDR stage: more than 20 intraretinal hemorrhages in each of 4 quadrants, venous beading in 2 quadrants, or prominent intraretinal microvascular abnormalities (IRMA) in 1 quadrant. Approximately 50% of adults with severe NPDR will progress to proliferative retinopathy within 1 year without treatment. The eye exam guide that explains the dilated exam process is our eye exams for people with diabetes article.
• Proliferative diabetic retinopathy (PDR) — the vision-threatening stage: New abnormal blood vessels grow from the surface of the retina (neovascularization) and extend into the vitreous — the gel-like substance filling the eye. These new vessels are structurally fragile and prone to bleeding into the vitreous (vitreous hemorrhage), causing sudden loss of vision (often described as a cloud, veil, or shower of floaters suddenly blocking vision). The fibrovascular tissue associated with neovascularization can contract and cause tractional retinal detachment — a surgical emergency. PDR requires urgent ophthalmologic intervention and, left untreated, frequently leads to severe, permanent vision loss. The broader diabetes complication context is in our diabetes complications: what adults should know guide.
• Diabetic macular edema (DME) — can occur at any NPDR or PDR stage: Macular edema — fluid accumulation within the layers of the macula (the central retina responsible for detailed central vision) — is the most common cause of vision loss from diabetic retinopathy. Unlike proliferative retinopathy (which predominantly causes peripheral vision loss initially), DME directly impairs central vision — the ability to read, recognize faces, and perform fine visual tasks. DME is treated with intravitreal anti-VEGF injections (ranibizumab, bevacizumab, aflibercept, faricimab) that reduce vascular permeability and macular fluid accumulation, typically requiring monthly to every-3-month injection schedules initially. The blood glucose monitoring that reduces retinopathy and DME risk is in our A1C testing schedule guide.

Treatment Options for Diabetic Retinopathy

When diabetic retinopathy reaches stages that carry significant vision-threatening risk, specific ophthalmic treatments can arrest progression and, in the case of macular edema, improve vision:

• Anti-VEGF intravitreal injections — the current first-line treatment for PDR and DME: Anti-VEGF agents (ranibizumab, bevacizumab, aflibercept, brolucizumab, faricimab) block the vascular endothelial growth factor that drives neovascularization and macular edema. Intravitreal injections (into the vitreous of the eye) are performed in an ophthalmologist’s office under local anesthesia and are remarkably effective — anti-VEGF therapy is now the preferred treatment for both diabetic macular edema (where it outperforms laser therapy in visual acuity preservation) and proliferative diabetic retinopathy (where it is equivalent or superior to panretinal photocoagulation in many settings). Treatment typically begins with monthly injections for 3–6 months, then shifts to an individualized maintenance schedule based on treatment response — typically every 6–12 weeks.
• Panretinal photocoagulation (PRP) laser — for proliferative retinopathy: PRP laser therapy destroys peripheral ischemic retina — reducing the oxygen-deprived tissue that produces the VEGF signal driving neovascularization. By destroying the ischemic peripheral retina (thousands of laser burns applied in sessions across multiple quadrants), PRP reduces the angiogenic drive and causes regression of new vessels in most eyes. PRP causes some permanent loss of peripheral and night vision (because the treated peripheral retina is destroyed), but preserves central vision — an acceptable trade-off for preventing vitreous hemorrhage and retinal detachment. PRP has been the gold standard for PDR management since the Diabetic Retinopathy Study in the 1970s and remains the most durable treatment for PDR in patients who cannot reliably attend frequent anti-VEGF injections.
• Vitrectomy surgery — for vitreous hemorrhage and tractional retinal detachment: When vitreous hemorrhage has not cleared spontaneously (typically within 3 months), or when tractional retinal detachment threatens or involves the macula, pars plana vitrectomy (surgical removal and replacement of the vitreous gel) is indicated. Modern vitrectomy techniques (25-gauge and 27-gauge microincision surgery) allow simultaneous removal of hemorrhage, membrane peeling, endolaser application, and retinal reattachment in a single procedure. Visual outcomes depend on the duration of the detachment, whether the macula was involved, and preoperative retinal function. The annual monitoring schedule that coordinates all diabetes eye care is in our annual diabetes care checklist. The complete eye exam guide for people with diabetes is our eye exams for people with diabetes article. The blood pressure monitoring that directly affects retinopathy progression is in our blood pressure monitoring in diabetes guide. The National Eye Institute’s diabetic retinopathy resources, the ADA’s retinopathy information, and the NIDDK’s diabetic eye disease overview provide authoritative clinical information on diabetic retinopathy stages, screening, and treatment.

How Blood Glucose and Blood Pressure Control Prevent Retinopathy

The primary prevention of diabetic retinopathy — and the most powerful tool for slowing its progression once it has developed — is consistent control of blood glucose and blood pressure over years and decades:

• Blood glucose control — the most important modifiable risk factor: The Diabetes Control and Complications Trial (DCCT) established definitively in Type 1 diabetes that intensive blood glucose control (A1C below 7.0%) reduced the risk of developing retinopathy by 76% and slowed the progression of existing retinopathy by 54% compared with conventional control (A1C approximately 9.0%). The EDIC follow-up study demonstrated that this benefit persisted for at least 10 years after the trial ended — even as the difference in A1C between the two groups narrowed post-trial — establishing the metabolic memory effect that shows early glucose control is particularly protective. In Type 2 diabetes, the UKPDS showed a significant 21% reduction in retinopathy progression with intensive blood glucose control. Each 1% reduction in A1C is associated with a significant reduction in retinopathy risk, and the evidence for blood glucose control benefit is more robust for retinopathy than for any other diabetes complication. The A1C monitoring guide is our A1C testing schedule guide.
• Blood pressure control — critical for both development and progression: The UKPDS blood pressure arm demonstrated that tight blood pressure control (target below 150/85 mmHg versus less tight control) reduced the risk of diabetic retinopathy progression by 34% and the risk of significant visual deterioration by 47%. This effect was independent of blood glucose control, confirming that hypertension directly drives retinal damage beyond the hyperglycemia mechanism — likely through increased hydrostatic pressure in retinal capillaries that worsens capillary leakage and ischemia. Blood pressure below 130/80 mmHg is the target in adults with diabetes and established retinopathy. ACE inhibitors and ARBs are preferred as antihypertensive agents in adults with diabetes given their renal protective effects and possible additional retinal protective effects through renin-angiotensin system blockade in the retina. The blood pressure monitoring that tracks whether the target is being achieved is in our blood pressure monitoring in diabetes guide.
• Lipid management — reducing hard exudate and macular edema risk: Elevated plasma lipids (particularly LDL cholesterol and triglycerides) contribute to hard exudate formation in the retina — the yellowish-white lipid deposits that can accumulate at the macula and directly threaten central vision. The FIELD trial showed that fenofibrate (a triglyceride-lowering agent) reduced the need for laser treatment for retinopathy by approximately 30% in adults with Type 2 diabetes, and the ACCORD Eye study found that combination therapy with fenofibrate and simvastatin significantly reduced retinopathy progression compared with simvastatin alone. While the evidence for fenofibrate in retinopathy is stronger than for statins specifically for retinal protection, statin therapy remains important for the cardiovascular protection it provides. The cholesterol monitoring context is our cholesterol monitoring in diabetes guide.
• Pregnancy and rapid blood glucose improvement — transient retinopathy worsening risk: Two situations can cause rapid worsening of pre-existing retinopathy even when blood glucose control appears to be improving: pregnancy (which is associated with transient retinopathy worsening, particularly in the second trimester, even with good glucose control — likely from local growth factor changes in the retina during pregnancy) and rapid normalization of chronically high blood glucose (for example, initiating intensive insulin therapy in an adult whose A1C had been above 10% for years can paradoxically worsen retinopathy over 6–12 months before the beneficial effect of improved control emerges). Adults in both of these situations should have more frequent ophthalmologic monitoring during the transition period. The overall diabetes eye care monitoring framework is in our eye exams for people with diabetes guide.

Warning Symptoms That Require Urgent Eye Evaluation

While diabetic retinopathy is asymptomatic in early stages, certain vision changes represent urgent ophthalmologic emergencies that cannot wait for a scheduled annual exam:

• Sudden onset of floaters, particularly a shower or cloud of floaters: A sudden increase in floaters — particularly a sudden shower of many small dots or a large floater — in an adult with diabetes can represent vitreous hemorrhage from bleeding neovascular vessels. This is a vision-threatening emergency that requires same-day or next-day ophthalmologic evaluation. Small vitreous hemorrhages may resolve spontaneously (the blood is gradually reabsorbed over weeks to months), but large hemorrhages or hemorrhages associated with other symptoms require urgent surgical assessment.
• Sudden vision loss or a curtain/shadow over part of the visual field: Sudden loss of vision or a fixed shadow over part of the visual field may represent retinal detachment — a surgical emergency where the retina has separated from the underlying retinal pigment epithelium. Retinal detachment requires urgent vitrectomy surgery; the longer the macula is detached, the worse the visual outcome even with successful surgical reattachment. Any adult with diabetes who experiences a curtain, shadow, or sudden peripheral vision loss should go to an emergency department or urgent ophthalmology immediately.
• Gradual blurring of central vision: Gradual blurring or distortion of central vision — reading difficulty, difficulty recognizing faces, straight lines appearing wavy (metamorphopsia) — can represent diabetic macular edema. While this is not an emergency in the same category as vitreous hemorrhage, it should be evaluated promptly (within days to weeks) rather than waiting for the next annual appointment. Anti-VEGF treatment is most effective at preserving and restoring central vision when started before significant visual acuity loss has accumulated. The annual monitoring schedule that ensures all diabetes complications including retinopathy are systematically assessed is in our annual diabetes care checklist. The complete diabetes complications framework placing retinopathy in context is our diabetes complications: what adults should know guide. The National Eye Institute’s retinopathy resources, the ADA’s retinopathy information, and the NIDDK’s diabetic eye disease overview provide authoritative guidance on diabetic retinopathy recognition, prevention, and treatment.

How Often Should Adults With Diabetes Have Eye Exams

The recommended frequency of ophthalmic screening for diabetic retinopathy depends on the type of diabetes, current retinopathy status, and pregnancy status:

• Type 2 diabetes — at diagnosis, then annually: Adults with Type 2 diabetes should have a dilated eye examination by an ophthalmologist or optometrist with expertise in diabetic eye disease at the time of diagnosis — because many adults with Type 2 diabetes have had undetected hyperglycemia for years before diagnosis, and retinopathy may already be present. Annual dilated examinations then continue every year. The ADA also accepts retinal photography (teleophthalmology) with remote reading as a validated screening alternative for adults without known retinopathy who do not have convenient access to eye care — but any detected abnormality requires referral to an ophthalmologist for formal evaluation and staging.
• Adults with no or mild retinopathy who are well controlled — may extend to every 1–2 years: Adults with Type 2 diabetes who have had two or more consecutive annual eye exams showing no retinopathy or only mild NPDR, with well-controlled blood glucose (A1C consistently below 7.0–7.5%) and blood pressure, may be candidates for extending the screening interval to every 2 years — a recommendation supported by recent ADA guidelines to reduce the burden of annual screening in low-risk individuals. This extension should only be made by the treating ophthalmologist based on the full clinical picture, not assumed by the patient.
• Adults with moderate or severe NPDR or diabetic macular edema — every 3–6 months: Adults with more advanced retinopathy require more frequent monitoring — typically every 3–6 months — to detect whether progression toward vision-threatening disease is occurring and whether treatment should be initiated or escalated. At this stage, collaboration between the primary care provider managing blood glucose and blood pressure and the ophthalmologist managing retinal disease is important for coordinated care.
• Pregnancy with pre-existing diabetes — intensive eye monitoring: Women with Type 1 or Type 2 diabetes who become pregnant should have a comprehensive eye exam in the first trimester and then every 1–3 months during pregnancy and for the first year postpartum. Retinopathy can worsen significantly during pregnancy — particularly in the second trimester — even with good glucose control, due to local hormonal changes affecting retinal vasculature. The complete annual diabetes monitoring schedule that coordinates eye exams with all other monitoring is in our annual diabetes care checklist. The detailed eye exam guide explaining what the dilated examination involves and what each finding means is our eye exams for people with diabetes article. The kidney monitoring that accompanies retinopathy monitoring as part of comprehensive microvascular complication surveillance is in our kidney tests for diabetes monitoring guide. The National Eye Institute’s retinopathy resources, the ADA’s eye health and retinopathy information, and the NIDDK’s diabetic eye disease prevention guide provide the authoritative clinical framework for retinopathy screening frequency and management in adults with diabetes.

The most important action any adult with diabetic retinopathy risk can take today is scheduling an annual dilated eye exam and not canceling it when vision seems fine. The absence of visual symptoms does not mean the retina is healthy — it means the damage has not yet reached the macula or progressed to the vision-threatening stage. The adults who preserve their vision for decades despite having diabetes are overwhelmingly those who attend eye exams consistently, maintain blood glucose and blood pressure control, and respond promptly to treatment when abnormalities are detected. Those who defer the eye exam because they see fine are precisely the group most at risk of discovering advanced retinopathy at a stage when vision loss has already occurred or when urgent treatment is needed to prevent immediate severe visual impairment. Annual dilated eye exams are among the most direct, high-value interventions in all of preventive diabetes care — and they require nothing more than showing up and having the examination performed. For any adult with diabetes who is uncertain whether their eye exam is current, asking at the next primary care or diabetes appointment — “When was my last dilated retinal exam?” — is an action that could protect their vision for the rest of their life.

Sources: American Diabetes Association — Standards of Medical Care in Diabetes, retinopathy screening and management recommendations; National Eye Institute — diabetic retinopathy overview, staging, and treatment evidence; NIDDK — diabetic eye disease prevention and management; global diabetic retinopathy prevalence (34 million affected worldwide; 40% of adults with Type 2 diabetes); leading cause of vision loss in adults aged 20–74 in the USA; NPDR staging — mild, moderate, severe (4-2-1 rule); proliferative diabetic retinopathy — neovascularization, vitreous hemorrhage, tractional retinal detachment; diabetic macular edema — mechanism, central vision impairment, anti-VEGF treatment evidence (DRCR.net Protocol T comparing anti-VEGF agents); Diabetic Retinopathy Study and Early Treatment Diabetic Retinopathy Study — panretinal photocoagulation evidence and high-risk PDR characteristics; anti-VEGF agents in PDR versus laser (DRCR.net Protocol S); vitrectomy for vitreous hemorrhage and tractional detachment; DCCT/EDIC and UKPDS — blood glucose and blood pressure control in retinopathy prevention.